A safety committee convened by the FDA has declared esketamine safe for severe depression. But isn't this drug the same as ketamine, an illegal street drug? A medical anthropologist explains.
Academic rigour, journalistic flair
Articles on FDA
Displaying 1 - 20 of 43 articles
Most Americans underestimate how many calories nutritionists recommend they consume each day, which means maybe you can probably have one more treat without feeling guilty.
Men who can't take drugs for erectile dysfunction and overweight people who can't lose weight sometimes turn to natural supplements, thinking they are safe. Many times, they are not.
E-cigarettes are hotly debated because of the uncertainty of whether they are a gateway to cigarette smoking for teens, or an aid to smoking cessation. One thing is clear: They are not biodegradable.
The Trump administration wants to streamline federal food safety efforts under one roof as part of a sweeping new plan to reorganize government.
The rising costs of generic drugs have led to outcries. In a search for solutions, four hospital systems are proposing to make drugs on their own. Could their idea work?
An increasing list of rare diseases can now be treated with gene therapy. But we need to figure out a way to make them affordable.
Congress has sent a bill to the White House. It gives terminally-ill patients more false hope than chances for a cure.
Health Canada proposes to increase fees to the pharmaceutical industry for prescription drug approval. This will compromise drug safety and is a risk to the health of the Canadian public.
Philip Morris has applied to the FDA to market a product that it says is safer than a cigarette, but its own data show that is not true.
The herb kratom has a large following and is so popular that it is sold in vending machines. The FDA recently issued a public warning about the herb, which contains low levels of opioids.
A successful gene therapy for the leading cause of sight loss in children is being reviewed by the FDA.
How can we fight the opioid epidemic? Redesign the drugs, rethink how we assess patients and mandate prescription monitoring.
Companies are exploiting a knowledge gap with consumers and fears of the supposed health hazards of certain ingredients with so-called absence labels.
FDA Director Scott Gottlieb has proposed discussions about drastically cutting nicotine levels in cigarettes. This could result in some of the biggest health gains in history.
In planes, trains and cars, we increasingly entrust our lives to automated safety systems. It's time for medical technology to catch up.
Reports about trace amounts of pesticides, like the EWG's Dirty Dozen, can leave people afraid to buy fruits and vegetables. But the hype is often overblown.
Intuitively, it might seem desirable to speed up access to medicines. But this means more drugs will be approved that may subsequently prove unsafe or ineffective.
Dogs are great companions, and they also are proving to be great research subjects for cancer. Here's how our canine friends are pointing to possible treatments in human cancer.
Lowering the threshold for FDA approval and feeding the agency less rigorous information will increase the likelihood of approvals of unsafe or ineffective drugs and devices.
Top contributors
-
Professor and Dean, School of Public Health, Georgia State University
-
Professor and Head of the Department of Pharmacy Practice, University of Connecticut
-
Postdoctoral research fellow, University of Adelaide
-
Research Leader, Critical and Ethical Mental Health research group, Robinson Research Institute, University of Adelaide
-
Senior lecturer in Pharmacology, University of Adelaide
-
Professor and Head of Clinical Research, National Centre for Immunisation Research and Surveillance, University of Sydney
-
Associate Professor, Deakin University
-
Senior Research Fellow, Bioethics, University of Sydney
-
Associate Professor Politics and Policy Studies, Deakin University
-
PhD candidate, University of Sydney
-
Professor of Medicine, University of Sydney
-
Research fellow, University of Sydney
-
Emeritus Professor of Clinical Sciences, University of Bristol
-
Nial Wheate is a Friend of The Conversation.
Associate Professor | Program Director, Undergraduate Pharmacy, University of Sydney
-
Ontario Research Chair in Bioethics and Public Policy, Queen's University, Ontario
